The right answers to frequently asked questions
Find the answers to all our products and services by clicking the links below.
What kind of samples can be processed with INVIEW Oncoexome Liquid Biopsy?
For INVIEW Oncoexome Liquid Biopsy, we accept fresh or retained plasma samples as well as already isolated cell-free DNA. Please refer to our Liquid Biopsy sample preparation sheet (see "Files"). The ctDNA is extracted from the blood plasma fraction.
For starting material such as DNA isolated from FFPE and tissue samples, please refer to our product Inview Human Exome.
How much starting material is required?
In general we require either 4 mL of plasma or 15 ng already isolated cell-free DNA (up to 30 µl / concentration > 0,5 ng/µl).
What pre-sequencing services are available?
Several pre-sequencing services are included in the Oncoexome product. These include ctDNA extraction from plasma and high- complexity library preparation with low duplicate rates. Exon targeting is accomplished with Agilent’s SureSelect platform, which offers superior exon enrichment and coverage uniformity.
What sequencing coverage should I use?
The required coverage depends on the required sensitivity of variant detection. You may choose the sequencing coverage you need for your individual project study objective.
We typically recommend 100x coverage based on experience gained from analysing cell-free DNA from more than 40,000 samples to date.
What kind of quality controls do you perform?
The quality and quantity of each sample will be determined upon receiving the sample. Further quality controls are performed at various steps of the process.
How should I choose between Oncoexome, Oncopanel and Oncotarget?
All three tests are based on liquid biopsy. The three products serve as powerful non-invasive tools for real-time cancer profiling with the ability to capture the entire heterogeneity of the disease.
INVIEW Oncoexome Liquid Biopsy is the first commercially available service for whole exome sequencing (WES) of ctDNA. With this service, you can obtain a comprehensive profile of all mutations present in the protein-coding regions of the genome. This product is suitable for a preliminary look at the genome of a suspected cancer patient, in cases where limited information regarding clinically relevant mutations is available.
INVIEW Oncopanel Liquid Biopsy is a comprehensive NGS panel for profiling important cancer mutations. It uses single-molecule PCR to target 50 known cancer genes including tumour suppressors, mutation hotspots and drug-resistance markers. The panel sets a new industry standard in terms of sequence coverage and uniformity with a sensitivity of about 1%.
INVIEW Oncotarget facilitates ultra-sensitive detection of clinically relevant cancer-specific point mutations, insertions, deletions and gene fusions in circulating tumour DNA down to an allele frequency of 0.1%. This approach is suitable for treatment monitoring as it is sensitive enough to detect a relapse at a very early stage.
How do I obtain my results and what form will they be in when delivered?
All deliverables (FAST-Q files and analyzed data) can be downloaded via your secure online account.
How soon after the blood draw should I ship the sample?
Blood samples have to be shipped to Eurofins Genomics within 24 hours after drawing blood. The sample must be stored in BCT Streck tubes. Samples may be stored and delivered at room temperature. Plasma samples have to be shipped on dry ice.
How many samples can I submit?
Eurofins Genomics accepts any number of samples in multiples of four.
Where should I send my samples?
Eurofins Genomics Europe Sequencing GmbH
Jakob-Stadler-Platz 7
78467 Konstanz
Germany
